Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Conclusion In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death.
Source: European Heart Journal - Category: Cardiology Source Type: research
More News: Cancer & Oncology | Cardiology | Cardiovascular | Chronic Kidney Disease | Dapagliflozin | Forxiga | Heart | Urology & Nephrology | Women